Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
Congressional Letter to Administration on…
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our…
Learn more
BIO Supporting Oxitec’s Experimental Use Permit …
The Biotechnology Innovation Organization (BIO) submits these comments in response to the U.S. Environmental Protection Agency’s (EPA) request for public input on the receipt of an application, 93167-EUP-2, from Oxitec Ltd requesting to amend and…
Learn more
BIO Signs Letter to House Leadership on Need to…
The undersigned organizations write to encourage policymakers to remove provisions in the Build Back Better Act that would curtail the effectiveness of Qualified Small Business Stock (QSBS) in incentivizing investment in innovative small businesses…
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Congressional Letter to Administration on Importance of Animal Biotechnology
October 8, 2021
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our…
BIO Supporting Oxitec’s Experimental Use Permit (EUP) for Biotech Mosquito
September 30, 2021
The Biotechnology Innovation Organization (BIO) submits these comments in response to the U.S. Environmental Protection Agency’s (EPA) request for public input on the receipt of an application, 93167-EUP-2, from Oxitec Ltd requesting to amend and…
BIO Signs Letter to House Leadership on Need to Protect Qualified Small Business Stock
September 30, 2021
The undersigned organizations write to encourage policymakers to remove provisions in the Build Back Better Act that would curtail the effectiveness of Qualified Small Business Stock (QSBS) in incentivizing investment in innovative small businesses…
BIO Testimony to House Agriculture Hearing on Carbon Markets
September 23, 2021
To meet the challenge of climate change, it is crucial to lead with science and U.S. innovation. We must incentivize the adoption of innovative, sustainable technologies and practices; and streamline and expedite regulatory pathways for breakthrough…
Supporting U.S. Food & Agriculture Innovation & Climate Objectives
September 23, 2021
Safe, secure, affordable & accessible food supply Hundreds of millions of Americans and people around the world rely on safe and nutritious U.S. agricultural products and foods. Americans have access to one of the safest, most diverse, most…
Open Letter to the President of the United States: The Need for U.S. Leadership in Global Vaccinations
August 10, 2021
We want to commend you and your Administration for the global distribution of millions of doses of the COVID-19 vaccines. Our friends in recipient countries are truly grateful. Nonetheless, in order to gain control of the pandemic, a much more…
BIO Comments on Core PROs in Cancer Clinical Trials
August 9, 2021
On Thursday, June 10th, 2021, the U.S. Food and Drug Administration (FDA) published a draft guidance, Core Patient-Reported Clinical Outcomes in Cancer Clinical Trials, providing recommendations to sponsors on the collection of a core set of patient…
BIO Submits Comments to the USPTO on Discretion to Institute Trials Before the Patent Trial and Appeal Board
August 6, 2021
BIO submitted comments to the United States Patent and Trademark Office in response to the USPTO's consideration of “the codification of its current policies and practices, or the modification thereof,” relating to the exercise of its discretion…
Cartier Esham’s Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases
July 30, 2021
BIO regularly publishes reports that help us assess the health of the biopharmaceutical pipeline across different diseases so that we can identify and remove barriers to providing next generation cures and treatments to patients and their families…
Phyllis Arthur's Testimony to Senate HELP Committee on Lessons Learned from Covid-19
July 27, 2021
COVID-19 will not be our last public health emergency.  We face numerous bio-threats from natural and bioterror threats.  Strong support for medical countermeasures R&D is critical to protecting our national security. Today I will…